Author: SK BIOSCIENCE

Posted Date:

March 18, 2026

SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support

SK BIOSCIENCE

March 18, 2026
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union

SK BIOSCIENCE

February 26, 2026
SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute

SK BIOSCIENCE

February 3, 2026
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

SK BIOSCIENCE

January 29, 2026
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding

SK BIOSCIENCE

January 27, 2026